SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Barclays downgrade of Joby to Underweight, citing cash burn and doubts about manufacturing capacity and market share, is driving the selloff and comparisons with upgraded rival Archer. Traders are divided between selling or switching to Archer and viewing the downgrade as a shakeout while maintaining confidence in Jobys technology, Toyota backing, and FAA progress.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase is drawing attention as traders weigh persistent solar-sector pressure from higher borrowing costs and weaker residential demand against its developing IQ SST opportunity for AI data-center power. U.S. production progress and planned demonstrations and customer pilots have fueled rebound and short-squeeze speculation, while skeptics caution that the new business is still unproven and near-term solar headwinds remain.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivaxs pullback is fueling debate over whether buyout hopes have outrun the near-term case for its ulcerative-colitis drug, obefazimod, despite positive Phase 3 data and a planned FDA filing. Bulls see value in the drugs potential and point to Crohns data as a future catalyst, while skeptics say the lack of a deal could leave the shares waiting on clinical and regulatory milestones; some also cite broader biotech weakness.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is drawing attention amid a sharp bank-stock pullback, with traders citing elevated Treasury yields and concern about the upcoming earnings outlook; the CEOs warning of weaker investment-banking fees and roughly flat trading revenue has added to the pressure. Sentiment is split between traders expecting further declines and buyers who see the pullback as an oversold opportunity ahead of results.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Oppenheimers upgrade to Outperform, citing rising contract values and early monetization of agentic-AI traffic, is driving attention to Fastly. Traders are reacting bullishly to the AI-growth thesis, while some question how much that traffic will translate into reported revenue and view upcoming results as a test of the thesis.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is drawing attention around a potential rebound in beaten-down Chinese internet and tech stocks, with traders pointing to bullish options activity, technical support and rotation into China tech. Others remain skeptical, citing the ETFs persistent downtrend, weak market fundamentals and regulatory and geopolitical risks.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention amid a recent pullback, which traders attribute to rising Treasury yields and money rotating back toward tech and growth stocks. The community is split between investors adding shares for long-term dividend income and those questioning the funds appeal versus CDs, cash, or growth-focused ETFs.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off on concerns that SpaceXs planned acquisition of low-band spectrum could help Starlink Mobile compete with established wireless carriers. Traders are split between viewing the threat as a long-term risk to subscribers and pricing and calling the selloff overdone given the time and infrastructure needed to build a competing network, alongside Verizons cash flows and dividend.

Cash Cat

A sharp pullback after a speculative rally is driving discussion, with traders debating whether CASHCAT is a pump-and-dump with weak support or a dip worth buying. Bulls cite its Robinhood-chain presence and claimed launchpad-driven buybacks and burns, while those claims and rumors of exchange or executive support remain unverified.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Rising yields and expectations ahead of Q3 earnings are weighing on bank stocks, with traders concerned about weaker lending and credit quality even as higher rates could support net interest income. Citi discussion is split between investors calling the pullback a buying opportunity and those anticipating cautious results or guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround 

Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company"))), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, todayread more...

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.read more...

Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call

Relmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High  - Time to Buy?

Relmada Therapeutics (NASDAQ:RLMD) Reaches New 1-Year High - Should You Buy...

Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Monday

Relmada Therapeutics (NASDAQ:RLMD) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-relmada-therapeutics-inc-stock...

Relmada Therapeutics (NASDAQ:RLMD) Trading Down 4.3% - Here's What Happened

Relmada Therapeutics (NASDAQ:RLMD) Shares Down 4.3% - What's Next...

Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$RLMD just bought 10k shares. If insiders can spend over 800k$ each, I can spend a little over 40k$

Lisa Netherton

$RLMD — Chief Executive Officer Sergio Traversa bought $828K 
 
· Chief Financial Officer Maged Shenouda bought $844K alongside them. 
· 2 insiders have bought $1.67M here in the last 1 days. 
· Chief executive — buying their own company. 
 
Insider grade: A (from their own prior trades) 
 
Not investment advice.

Form4 - Insider trade alerts

$RLMD results of phase 2 are based on a monocentric trial (1 site only) in.... israel... 

I would bet my life on this that it will not repeat the exact efficacy results seen in israel. Lots of examples of fraud there. Fact they bought the drug for pennies on the dollar tells you the entire story.

metalcook

$RLMD Finally made up my mind and pulled the trigger after a long tumultuous journey with Sergio Traversa, the Keyman of Rel-1017. After the acquisition of Trigone's NDV-01 I thought there would be a change in the management and new faces will enter in the BOD, but unfortunately, I see that the organism is manifesting similar morphological patterns once again. Learning to take a small loss is a valuable trait that I am still learning to overcome the resistance of taking the timely loss when my buying hypothesis is invalidated. Departure of Dr. Raj Pruthi as CMO and reading his LinkedIn profile update was the first serious warning for me. I think it was Uy Ear of Mizuho who asked Sergio Traversa - "why did Trigone partner with you", my own personal conclusion led me to take the bets off today. Good luck to you if you are reading this, but first and foremost, please DO your OWN Due Diligence.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RLMD Relmada Therapeutics Inc

Fundamentals

Latest RLMD News